Greater Tulsa Reporter
Cancer Treatment Centers of America (CTCA) is currently enrolling patients nationwide, across its five-hospital system, to the Targeted Agent and Profiling Utilization Registry (TAPUR) Study-the American Society of Clinical Oncology’s (ASCO) first-ever clinical trial.
The study will evaluate molecularly-targeted cancer drugs and collect data on clinical outcomes to learn about additional uses of these drugs outside of indications already approved by the Food and Drug Administration (FDA).
CTCA’s five hospitals are located in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa.
CTCA is the first hospital in the Atlanta, Chicago, Philadelphia, Phoenix and Tulsa area to offer patient access to the TAPUR trial.
“We are excited to have CTCA join the TAPUR Study. Their national reach allows us to provide access to the trial to a diverse group of patients,” says ASCO Chief Medical Officer Richard L. Schilsky, MD, FACP, FASCO. “With TAPUR, CTCA patients have the potential to benefit from targeted therapies that have already demonstrated effectiveness in other cancer types.”
The trial involves broader opportunity for participation than in many cancer clinical trials-with the hope of enabling more patients to participate. Eligible participants include those who have an advanced solid tumor, multiple myeloma, or B cell non-Hodgkin lymphoma, are no longer benefiting from standard anti-cancer treatments, or for whom no acceptable standard treatment is available. Patients enrolled in the study will have access to experimental targeted cancer drugs at no cost.
The goals of the study are:
• Learn how approved drugs might work against different tumor types that harbor the drug target;
• Find out how genomic or molecular tests are used to care for people with advanced cancer;
• Use the study results to help inform future studies and aid in the care of people with cancer.
“Being part of the ASCO TAPUR Study . . . allows us to offer eligible cancer patients access to new treatment options under investigation,” says Maurie Markman, MD, president of medicine and science at CTCA. “In addition, our unique and robust precision medicine program helps remove both the financial and educational barriers patients experience when accessing genomic sequencing, which determines eligibility for this landmark trial.”